Advanced

Low-molecular-weight carbohydrate Pentaisomaltose may replace dimethyl sulfoxide as a safer cryoprotectant for cryopreservation of peripheral blood stem cells

Svalgaard, Jesper Dyrendom; Haastrup, Eva Kannik; Glovinski, Peter Viktor; Reckzeh, Kristian LU ; Holst, Bjørn; Gørløv, Jette Sønderskov; Hansen, Morten Bagge; Moench, Kim Theilgaard LU ; Clausen, Christian and Fischer-Nielsen, Anne (2016) In Transfusion 56(5). p.95-1088
Abstract

BACKGROUND: Cryopreserved hematopoietic stem cell products are widely used for certain hematologic malignancies. Dimethyl sulfoxide (DMSO) is the most widely used cryoprotective agent (CPA) today, but due to indications of cellular toxicity, changes of the cellular epigenetic state, and patient-related side effects, there is an increasing demand for DMSO-free alternatives. We therefore investigated whether Pentaisomaltose (PIM), a low-molecular-weight carbohydrate (1 kDa), can be used for cryopreservation of peripheral blood stem cells, more specifically hematopoietic progenitor cell apheresis (HPC(A)) product. STUDY DESIGN AND METHODS: We cryopreserved patient or donor HPC(A) products using 10% DMSO or 16% PIM and quantified the... (More)

BACKGROUND: Cryopreserved hematopoietic stem cell products are widely used for certain hematologic malignancies. Dimethyl sulfoxide (DMSO) is the most widely used cryoprotective agent (CPA) today, but due to indications of cellular toxicity, changes of the cellular epigenetic state, and patient-related side effects, there is an increasing demand for DMSO-free alternatives. We therefore investigated whether Pentaisomaltose (PIM), a low-molecular-weight carbohydrate (1 kDa), can be used for cryopreservation of peripheral blood stem cells, more specifically hematopoietic progenitor cell apheresis (HPC(A)) product. STUDY DESIGN AND METHODS: We cryopreserved patient or donor HPC(A) products using 10% DMSO or 16% PIM and quantified the recovery of CD34+ cells and CD34+ subpopulations by multicolor flow cytometry. In addition, we compared the frequency of HPCs after DMSO and PIM cryopreservation using the colony-forming cells (CFCs) assay. RESULTS: The mean CD34+ cell recovery was 56.3±23.7% (11.4%-97.3%) and 58.2±10.0% (45.7%-76.9%) for 10% DMSO and 16% PIM, respectively. The distribution of CD34+ cell subpopulations was similar when comparing DMSO or PIM as CPA. CFC assay showed mean colony numbers of 70.7±25.4 (range, 37.8-115.5) and 67.7±15.7 (range, 48-86) for 10% DMSO and 16% PIM, respectively. CONCLUSION: Our findings demonstrate that PIM cryopreservation of HPC(A) products provides recovery of CD34+ cells, CD34+ subpopulations, and CFCs similar to that of DMSO cryopreservation and therefore may have the potential to be used for cryopreservation of peripheral blood stem cells.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Stem cells, Cryoprotectant, crypreservation
in
Transfusion
volume
56
issue
5
pages
95 - 1088
publisher
Wiley-Blackwell
external identifiers
  • Scopus:84961218463
ISSN
0041-1132
DOI
10.1111/trf.13543
language
English
LU publication?
no
id
e5a29651-fc69-4341-b566-60199dd1d21e
date added to LUP
2016-05-18 16:56:19
date last changed
2016-11-08 15:05:32
@misc{e5a29651-fc69-4341-b566-60199dd1d21e,
  abstract     = {<p>BACKGROUND: Cryopreserved hematopoietic stem cell products are widely used for certain hematologic malignancies. Dimethyl sulfoxide (DMSO) is the most widely used cryoprotective agent (CPA) today, but due to indications of cellular toxicity, changes of the cellular epigenetic state, and patient-related side effects, there is an increasing demand for DMSO-free alternatives. We therefore investigated whether Pentaisomaltose (PIM), a low-molecular-weight carbohydrate (1 kDa), can be used for cryopreservation of peripheral blood stem cells, more specifically hematopoietic progenitor cell apheresis (HPC(A)) product. STUDY DESIGN AND METHODS: We cryopreserved patient or donor HPC(A) products using 10% DMSO or 16% PIM and quantified the recovery of CD34+ cells and CD34+ subpopulations by multicolor flow cytometry. In addition, we compared the frequency of HPCs after DMSO and PIM cryopreservation using the colony-forming cells (CFCs) assay. RESULTS: The mean CD34+ cell recovery was 56.3±23.7% (11.4%-97.3%) and 58.2±10.0% (45.7%-76.9%) for 10% DMSO and 16% PIM, respectively. The distribution of CD34+ cell subpopulations was similar when comparing DMSO or PIM as CPA. CFC assay showed mean colony numbers of 70.7±25.4 (range, 37.8-115.5) and 67.7±15.7 (range, 48-86) for 10% DMSO and 16% PIM, respectively. CONCLUSION: Our findings demonstrate that PIM cryopreservation of HPC(A) products provides recovery of CD34+ cells, CD34+ subpopulations, and CFCs similar to that of DMSO cryopreservation and therefore may have the potential to be used for cryopreservation of peripheral blood stem cells.</p>},
  author       = {Svalgaard, Jesper Dyrendom and Haastrup, Eva Kannik and Glovinski, Peter Viktor and Reckzeh, Kristian and Holst, Bjørn and Gørløv, Jette Sønderskov and Hansen, Morten Bagge and Moench, Kim Theilgaard and Clausen, Christian and Fischer-Nielsen, Anne},
  issn         = {0041-1132},
  keyword      = {Stem cells,Cryoprotectant,crypreservation},
  language     = {eng},
  number       = {5},
  pages        = {95--1088},
  publisher    = {ARRAY(0x94f5628)},
  series       = {Transfusion},
  title        = {Low-molecular-weight carbohydrate Pentaisomaltose may replace dimethyl sulfoxide as a safer cryoprotectant for cryopreservation of peripheral blood stem cells},
  url          = {http://dx.doi.org/10.1111/trf.13543},
  volume       = {56},
  year         = {2016},
}